EGFR and microvessel density in canine malignant mammary tumours

Research in Veterinary Science

Volumn 95, Issue 3, 2013, Pages 1094-1099

  Carvalho, Maria Isabel ^a   Guimarães, Maria João ^b   Pires, Isabel ^c   Prada, Justina ^c   Silva Carvalho, Ricardo ^d,e   Lopes, Carlos ^a   Queiroga, Felisbina L ^a,b  

^a UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^d UNIVERSITY OF MINHO   (Portugal)

^e UNIVERSITY OF MINHO   (Portugal)

Author keywords

Angiogenesis; Canine mammary tumours; CD31; EGFR; MVD

Indexed keywords

CD31 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY LABELING; ANTIGEN EXPRESSION; ARTICLE; BASAL CELL; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CAPILLARY DENSITY; CELL LABELING; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOG; DOG DISEASE; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALIGNANT NEOPLASTIC DISEASE; MITOSIS INDEX; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; ONCOLOGICAL PARAMETERS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR AGGRESSIVENESS; TUMOR NECROSIS; TUMOR VOLUME;

ANGIOGENESIS; CANINE MAMMARY TUMOURS; CD31; EGFR; MVD;

ANIMALS; ANTIGENS, CD31; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY NEOPLASMS, ANIMAL; MICROVESSELS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84887997047     PISSN: 00345288     EISSN: 15322661     Source Type: Journal    
DOI: 10.1016/j.rvsc.2013.09.003     Document Type: Article

References (58)

1. Baselga J., Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. Journal of Clinical Oncology 2005, 23:2445-2459.
2. Baumann M., Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiotherapy and Oncology 2004, 72:257-266.
3. Carvalho M.I., Pires I., Prada J., Queiroga F.L. T-lymphocytic infiltrate in canine mammary tumours: clinic and prognostic implications. In Vivo 2011, 25:963-969.
4. Ceccarelli C., Piazzi G., Paterini P., Pantaleo M.A., Taffurelli M., Santini D., Martinelli G.N., Biasco G. Concurrent EGFr and Cox-2 expression in colorectal cancer: proliferation impact and tumour spreading. Annals of Oncology 2005, (Suppl. 4):iv74-iv79.
5. Cristofanilli M., Charnsangavej C., Hortobagyi G.N. Angiogenesis modulation in cancer research: novel clinical approaches. Nature Reviews Drug Discovery 2002, 1:415-426.
6. Dannenberg A.J., Lippman S.M., Mann J.R., Subbaramaiah K., DuBois R.N. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. Journal of Clinical Oncology 2005, 23:254-266.
7. De Luca A., Carotenuto A., Rachiglio A., Gallo M., Maiello M.R., Aldinucci D., Pinto A., Normanno N. The role of the EGFR signaling in tumor microenvironment. Journal of Cellular Physiology 2008, 214:559-567.
8. De Luca A., Gallo M., Aldinucci D., Ribatti D., Lamura L., D'Alessio A., De Filippi R., Pinto A., Normanno N. Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. Journal of Cellular Physiology 2011, 226:2131-2138.
9. Demetri G.D. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Seminars in Oncology 2011, 38(Suppl 1):S10-19.
10. Diaz R., Nguewa P.A., Parrondo R., Perez-Stable C., Manrique I., Redrado M., Catena R., Collantes M., Penuelas I., Diaz-Gonzalez J.A., Calvo A. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer 2010, 10:188.
11. Donnay I., Rauis J., Wouters-Ballman P., Devleeschouwer N., Leclercq G., Verstegen J.P. Receptors for oestrogen, progesterone and epidermal growth factor in normal and tumorous canine mammary tissues. Journal of Reproduction and Fertility 1993, 47:501-512.
12. Donnay I., Devleeschouwer N., Wouters-Ballman P., Leclercq G., Verstegen J. Relationship between receptors for epidermal growth factor and steroid hormones in normal, dysplastic and neoplastic canine mammary tissues. Research in Veterinary Science 1996, 60:251-254.
13. Fahey C.E., Milner R.J., Kow K., Bacon N.J., Salute M.E. Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells. Anti-Cancer Drugs 2013, 24:519-526.
14. Fox S.B., Leek R.D., Smith K., Hollyer J., Greenall M., Harris A.L. Tumor angiogenesis in node-negative breast carcinomas-relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Research and Treatment 1994, 29:109-116.
15. Gama A., Gartner F., Alves A., Schmitt F. Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues. Research in Veterinary Science 2009, 87:432-437.
16. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000, 5(Suppl. 1):37-44.
17. Gasparini G. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Critical Reviews in Oncology/Hematology 2001, 37:97-114.
18. Goldschmidt M., Pena L., Rasotto R., Zappulli V. Classification and grading of canine mammary tumors. Veterinary Pathology 2011, 48:117-131.
19. Graham J.C., Myers R.K. The prognostic significance of angiogenesis in canine mammary tumors. Journal of Veterinary Internal Medicine 1999, 13:416-418.
20. Guimarães M.J., Carvalho M.I., Pires I., Prada J., Gonzalez Gil A., Lopes C., Queiroga F.L. Concurrent expression of cyclo-oxygenase-2 and epidermal growth factor receptor in canine malignant mammary tumours. Journal of Comparative Pathology 2013, 10.1016/j.jcpa.2013.07.005.
21. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
22. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
23. Herbst R.S. Review of epidermal growth factor receptor biology. International Journal of Radiation Oncology Biology Physics 2004, 59:21-26.
24. Iivanainen E., Lauttia S., Zhang N., Tvorogov D., Kulmala J., Grenman R., Salven P., Elenius K. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels. Microvascular Research 2009, 78:278-285.
25. Jin B.J., Min H.J., Jeong J.H., Park C.W., Lee S.H. Expression of EGFR and microvessel density in middle ear cholesteatoma. Clinical and Experimental Otorhinolaryngology 2011, 4:67-71.
26. Katanasaka Y., Kodera Y., Kitamura Y., Morimoto T., Tamura T., Koizumi F. Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma. Molecular Cancer 2013, 12:31.
27. Kim E.S., Khuri F.R., Herbst R.S. Epidermal growth factor receptor biology (IMC-C225). Current Opinion in Oncology 2001, 13:506-513.
28. Kim N.H., Lim H.Y., Im K.S., Kim J.H., Sur J.H. Identification of triple-negative and basal-like canine mammary carcinomas using four basal markers. Journal of Comparative Pathology 2013, 148:298-306.
29. Klijn J.G., Berns P.M., Schmitz P.I., Foekens J.A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocrine Reviews 1992, 13:3-17.
30. Lavalle G.E., Bertagnolli A.C., Tavares W.L., Cassali G.D. Cox-2 expression in canine mammary carcinomas: correlation with angiogenesis and overall survival. Veterinary Pathology 2009, 46:1275-1280.
31. Leek R.D. The prognostic role of angiogenesis in breast cancer. Anticancer Research 2001, 21:4325-4331.
32. Locopo N., Fanelli M., Gasparini G. Clinical significance of angiogenic factors in breast cancer. Breast Cancer Research and Treatment 1998, 52:159-173.
33. Lyles S.E., Milner R.J., Kow K., Salute M.E. In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines. Veterinary and Comparative Oncology 2012, 10:223-235.
34. Misdorp W., Else R.W., Hellmen E., Lipscomb T.P. Histological Classification of Mammary Tumors of the Dog and the Cat 1999, Armed Forces Institute of Pathology in cooperation with the American Registry of Pathology and the World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology, Washington.
35. Mitry E., Hammel P., Deplanque G., Mornex F., Levy P., Seitz J.F., Moussy A., Kinet J.P., Hermine O., Rougier P., Raymond E. Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology 2010, 66:395-403.
36. Muhammadnejad S., Muhammadnejad A., Haddadi M., Oghabian M.A., Mohagheghi M.A., Tirgari F., Sadeghi-Fazel F., Amanpour S. Correlation of microvessel density with nuclear pleomorphism, mitotic count and vascular invasion in breast and prostate cancers at preclinical and clinical levels. Asian Pacific Journal of Cancer Prevention 2013, 14:63-68.
37. Nerurkar V.R., Seshadri R., Mulherkar R., Ishwad C.S., Lalitha V.S., Naik S.N. Receptors for epidermal growth factor and estradiol in canine mammary tumors. International Journal of Cancer 1987, 40:230-232.
38. Nickerson N.K., Mohammad K.S., Gilmore J.L., Crismore E., Bruzzaniti A., Guise T.A., Foley J. Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad. PLoS One 2012, 7:e30255.
39. Nieto Y., Woods J., Nawaz F., Baron A., Jones R.B., Shpall E.J., Nawaz S. Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. British Journal of Cancer 2007, 97:391-397.
40. Normanno N., Gullick W.J. Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application?. Endocrine-Related Cancer 2006, 13:3-6.
41. Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R., Carotenuto A., De Feo G., Caponigro F., Salomon D.S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366:2-16.
42. Owens L. Classification of Tumors in Domestic Animals 1980, World Health Organization, Geneva, Switzerland. first ed.
43. Perrotte P., Matsumoto T., Inoue K., Kuniyasu H., Eve B.Y., Hicklin D.J., Radinsky R., Dinney C.P. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clinical Cancer Research 1999, 5:257-265.
44. Pouyssegur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443.
45. Queiroga F.L., Pires I., Parente M., Gregorio H., Lopes C.S. COX-2 over-expression correlates with VEGF and tumour angiogenesis in canine mammary cancer. Veterinary Journal 2011, 189:77-82.
46. Rak J.W., St Croix B.D., Kerbel R.S. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anti-Cancer Drugs 1995, 6:3-18.
47. Restucci B., De Vico G., Maiolino P. Evaluation of angiogenesis in canine mammary tumors by quantitative platelet endothelial cell adhesion molecule immunohistochemistry. Veterinary Pathology 2000, 37:297-301.
48. Rowe R.W., Tomoda M., Strebel F.R., Jenkins G.N., Stephens L.C., Bull J.M. The natural progression of microvasculature in primary tumor and lymph node metastases in a breast carcinoma model: relationship between microvessel density, vascular endothelial growth factor expression, and metastatic invasion. Cancer Biology & Therapy 2004, 3:408-414.
49. Rutteman G.R., Foekens J.A., Portengen H., Vos J.H., Blankenstein M.A., Teske E., Cornelisse C.J., Misdorp W. Expression of epidermal growth factor receptor (EGFR) in non-affected and tumorous mammary tissue of female dogs. Breast Cancer Research and Treatment 1994, 30:139-146.
50. Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clinical Cancer Research 2006, 12:5268-5272.
51. Schor A.M., Pazouki S., Morris J., Smither R.L., Chandrachud L.M., Pendleton N. Heterogeneity in microvascular density in lung tumours: comparison with normal bronchus. British Journal of Cancer 1998, 77:946-951.
52. Shien T., Tashiro T., Omatsu M., Masuda T., Furuta K., Sato N., Akashi-Tanaka S., Uehara M., Iwamoto E., Kinoshita T., Fukutomi T., Tsuda H., Hasegawa T. Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation. Journal of Clinical Pathology 2005, 58:1299-1304.
53. Sleeckx N., Van Brantegem L., Fransen E., Van den Eynden G., Casteleyn C., Veldhuis Kroeze E., Van Ginneken C. Evaluation of immunohistochemical markers of lymphatic and blood vessels in canine mammary tumours. Journal of Comparative Pathology 2013, 148:307-317.
54. Takeuchi Y., Fujino Y., Fukushima K., Watanabe M., Nakagawa T., Ohno K., Sasaki N., Sugano S., Tsujimoto H. Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses. Journal of Veterinary Pharmacology and Therapeutics 2012, 35:97-104.
55. Tsutsui S., Ohno S., Murakami S., Hachitanda Y., Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Research and Treatment 2002, 71:67-75.
56. Walker R.A., Dearing S.J. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Research and Treatment 1999, 53:167-176.
57. Weidner N., Gasparini G. Determination of epidermal growth factor receptor provides additional prognostic information to measuring tumor angiogenesis in breast carcinoma patients. Breast Cancer Research and Treatment 1994, 29:97-107.
58. Zetter B.R. Angiogenesis and tumor metastasis. Annual Review of Medicine 1998, 49:407-424.